Key facts
- It has raised $926.0M across 2 recorded rounds; the latest was Later Stage VC (Series D) ($401.0M) in May 2023.
- 4 institutional filers report fund marks on ElevateBio across 35 filings.
Free account
See the evidence behind this price
- ·Post-money valuations for all 2 rounds
- ·Watchlist + deal alerts for ElevateBio
Create free account
No card required
Funding rounds
2 roundsMay 2023Later Stage VC (Series D)$401.0M▮
Jan 2021Later Stage VC (Series C)$525.0M▮
About ElevateBio
- Industry
- Discovery Tools (Healthcare)
PA Mark — not yet priced
ElevateBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.
Recorded secondary trades
No prints on record
No secondary trades in ElevateBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
4 filers · latest Jun 20264 SEC-registered funds reported 35 fair-value marks on ElevateBio between Apr 2025 and Jun 2026. Filer-level marks and implied $/share are available to Pro members.